Vitamin D

Vitamin D has been studied in 2,177 papers since 1978: 678 trials and 510 observational studies in people, 83 in animals, 10 in cells, 846 reviews; 496 in the past year. Its furthest trials in people are at phase 3. The newest story, Nov 13, 2026: “Low vitamin D linked to greater frailty in adults”.

InterventionPhase 3

2,177 papers study it2,055 more mention it2,136 findingsUpdated

MeSH

Research on it is growing 19% faster than aging research as a whole: 79 papers in the latest year counted

Part of Rhonda Patrick's supplement routine and David Sinclair's daily regimen in LifespanMore supplements

104 new papers in 30 daysSee all 4,014 papers on vitamin D

At a glance

Independent labs report longer lifespan with cholecalciferol in mice and reduced senescence with calcitriol in human cells. Human trials report mortality reductions or no clear effect, with mixed telomere and physical-function results. Some trials across all uses remain unreported over a year after ending; some papers declare ties to developer Merck & Co., and a trial is company-sponsored.

2,136 findings in 985 papers from 1982 to 2026, 90 of them since April 2026

Independent labs found the same change in cells, worms or flies, mice and people. 430 independent labs in 58 countries; 307 trials, 43 about aging, 120 with no results posted.

“RR = 0.96 (95% CI [0.92, 1.00]), p = 0.04.”
Vitamin D Supplementation and Mortality in the Elderly: A Review of a Meta-Analysis of Randomized Controlled Trials Using the REB MethodFundamental & clinical pharmacology2026doi:10.1111/fcp.70112

360 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 430 independent labs in 58 countries
  • 360 findings against
  • 307 trials, 43 about aging, 120 with no results posted
  • Funders: National Institutes of Health and others
  • 121 of 1,924 findings with company ties
  • 1 of 307 trials sponsored by its developers
  • Human trial524
  • Humans502
  • Animals76
  • Model organisms6
  • Cells10
  • In silico16

397 studies gave vitamin D to people and measured what changed.

What changedDesignPeopleSource

down: Decreases fasting blood glucose112.6 ± 8.4 to 102.4 ± 7.3 mg/dL; greater improvement than controls, P < 0.001

up: Increases 25-hydroxyvitamin D18.4 ± 4.5 to 27.6 ± 2.8 ng/mL

Trial3 months90 people18-65 yearsAdults with prediabetes; supplementation plus lifestyle advice compared with lifestyle advice aloneThe Nigerian postgraduate medical journal, Nov 2, 2026

down: Lowers the risk of mortalityRR = 0.96 (95% CI [0.92, 1.00], p = 0.04)

Review of trials2 and 6.1 years30,320 people pooledminimum age of 50 yearsPopulation aged over 75 yearsFundamental & clinical pharmacology, Oct 2, 2026

no change: Has no effect on plasma ADRD biomarkers

down: Decreases NfL-16.2% (95% CI: −30.5% to 1.1%)

Randomized trial4‐year929 people49.2% were femalesmean age was 65 yearsVITAL participants who lived near an affiliated National Institutes of Health–sponsored Harvard Catalyst–Clinical Translational Science Center in Boston, MassachusettsAlzheimer's & dementia (New York, N. Y.), Sep 14, 2026

down: Decreases fasting blood glucose

down: Decreases insulinMD = −0.30; 95% CI –0.56 to −0.03

down: Decreases HOMA-IRMD = −2.82; 95% CI, –5.06 to −0.57

Review of trialsAdults with prediabetesNutrition reviews, Sep 10, 2026

up: Increases 25-hydroxyvitamin DP < 0.01

Trial24-month520 peopleaged ≥65 yearsOlder adultsPreventive Medicine Research & Reviews, Sep 8, 2026

What did lifespan studies of vitamin D find?

DrugAge

DrugAge records 5 results from 2 papers: 5 in C. elegans. Average lifespan is the mean or the median, as each paper reports it.

What did studies of vitamin D find?

306

Studies of vitamin D measured 306 outcomes; the most studied are 25-hydroxyvitamin D (37 studies), physical function (13) and inflammation (13).

25-hydroxyvitamin D

upin humans37

37 studies
  1. Cholecalciferol increases 25-hydroxyvitamin D in humans (Adults with prediabetes receiving supplementation plus lifestyle advice) (18.4 ± 4.5 to 27.6 ± 2.8 ng/mL).

    “Serum 25(OH) D rose from 18.4 ± 4.5 to 27.6 ± 2.8 ng/mL ( P < 0.001).”

    Human trialAdults with prediabetes receiving supplementation plus lifestyle adviceserum2000 IU once daily3 monthsn = 45

    Effects of Vitamin D 3 Supplementation on Glycaemic Parameters and Insulin Sensitivity in Pre-diabetic Adults: A Prospective Controlled Interventional Study

    The Nigerian postgraduate medical journal

  2. Vitamin D increases 25-hydroxyvitamin D in humans (P < 0.01).

    “Vitamin D supplementation improved serum 25(OH) D levels ( P < 0.01).”

    Human trial24-monthn = 520

    Prevention of Fracture Risk among Older Long-term Care Residents: A Prospective Study from India

    Preventive Medicine Research & Reviews

  3. Cholecalciferol increases 25-hydroxyvitamin D in humans (73.0 vs 99.7 vs 120.4 nmol/L).

    “After 12 months, the concentrations were 73.0 ± 17.8, 99.7 ± 21.1 and 120.4 ± 21.8 nmol/L in the placebo, 1600 IU/day and 3200 IU/day arms, respectively (P < 0.001).”

    Human trial12 monthsn = 550

    The effect of vitamin D₃ supplementation on fracture incidence in an aging population - The Finnish vitamin D trial

    Bone

  4. Cholecalciferol increases 25-hydroxyvitamin D in humans (T-scores -1.5 to -2.5) (38.2 ± 7.5 ng/mL vs 28.5 ± 6.8 ng/mL).

    “Mean serum 25(OH)D levels were substantially higher (p = 0.003) in the liposomal group (38.2 ± 7.5 ng/mL) than those in the control cholecalciferol group (28.5 ± 6.8 ng/mL).”

    Human trialT-scores -1.5 to -2.5liposomal800 IU/day + 1000 mg calcium24 monthsfemalesn = 153

    Vitamin D supplementation and bone health in post-menopausal women: a 24-month randomized controlled intervention with enhanced bioavailability formulations

    European journal of clinical nutrition

  5. Cholecalciferol increases 25-hydroxyvitamin D in humans (vitamin D deficiency).

    “Both groups showed significant increases in serum 25(OH)D levels and reductions in PTH from baseline.”

    Human trialvitamin D deficiencyoral10 weeksn = 50

    Efficacy and safety of oral versus high dose intramuscular vitamin D therapy in elderly patients: A randomized controlled study

    Indian Journal of Orthopaedics Surgery

  6. Cholecalciferol increases 25-hydroxyvitamin D in humans (postmenopausal women with T2DM).

    “Serum 25(OH)D and HDL-c levels increased over time during the follow-up period.”

    Human trialpostmenopausal women with T2DM1000 IU/day for 12 months, followed by 2000 IU/day for another 12 months24 monthsfemalesn = 34

    Long-Term Cholecalciferol Supplementation and Metabolic Parameters in Postmenopausal Women with Type 2 Diabetes Mellitus: A Longitudinal Prospective Study

    Diabetology

  7. Cholecalciferol increases 25-hydroxyvitamin D in vitamin D-deficient hemodialysis patients (89.78 ± 33.43 nmol/L at 6 months).

    “The cholecalciferol supplemented group's 25OHD rose to 89.78 ± 33.43 nmol/L at 6 months”

    Human trialin vitamin D-deficient hemodialysis patients100 000 IU monthly oral6 monthsn = 70

    Cholecalciferol and muscle strength in hemodialysis patients: results from the randomized VITADIAL trial

    Clinical kidney journal

  8. Cholecalciferol increases 25-hydroxyvitamin D in humans.

    “allocation to vitamin D3 resulted in a dose-dependent increase in 25-hydroxy-vitamin D (25(OH)D) levels”

    Human trial2000 IU/d or 4000 IU/dn = 305

    Effects of vitamin D on biochemical markers of osteoporosis: a meta-analysis of randomised trials

    The British journal of nutrition

  9. Cholecalciferol increases 25-hydroxyvitamin D in humans (mild to moderate asthma) (p < 0.001).

    “Serum 25(OH)D increased significantly in Groups A and C (p < 0.001) but remained unchanged in Group B.”

    Human trialmild to moderate asthma12 weeks

    Combined effect of pulmonary rehabilitation and vitamin D supplementation on pulmonary function tests in asthma patients

    The Journal of asthma : official journal of the Association for the Care of Asthma

  10. Cholecalciferol increases 25-hydroxyvitamin D in adult epilepsy patients treated with enzymatic antiseizure medications (10.67 ± 8.16 vs. –1.29 ± 3.96 ng/mL).

    “Vitamin D supplementation yielded a significantly greater increase in serum 25(OH)D (10.67 ± 8.16 vs. –1.29 ± 3.96 ng/mL; p < 0.001)”

    Human trialin adult epilepsy patients treated with enzymatic antiseizure medications2,000 IU/day12 weeks

    Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial

    Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina

All 40

More on 25-hydroxyvitamin D

Physical function

no changein humans9upin humans5

13 studies
  1. Vitamin D improves physical function in humans (osteosarcoma after bone marrow stem cell transplantation) (P < 0.05).

    “improvement observed in the mentioned variables in the exercise training with vitamin D group was more than exercise training alone ( P < 0.05).”

    Human trialosteosarcoma after bone marrow stem cell transplantation10 weeksfemalesn = 50

    The effect of exercise training with vitamin D consumption on physical performance and quality of life of people with osteosarcoma cancer after bone marrow stem cell transplantation

    Comparative Exercise Physiology

  2. Ergocalciferol improves physical function in humans.

    “The vitamin D group demonstrated significant improvements in skeletal muscle mass, physical function, and quality of life scores compared to the control group”

    Human trial12 weeksn = 84

    Effect of vitamin D supplementation on skeletal muscle function and quality of life in patients with chronic intestinal failure: a randomized controlled trial : Clean version

    Journal of translational medicine

  3. Ergocalciferol improves physical function in humans (chronic intestinal failure and vitamin D deficiency) (p < 0.05).

    “clinically meaningful improvements in the appendicular skeletal muscle mass index, handgrip strength, 6-meter walking speed”

    Human trialchronic intestinal failure and vitamin D deficiency600,000 units every two weeks10 weeksn = 84

    Effect of vitamin D supplementation on skeletal muscle function and quality of life in patients with chronic intestinal failure: a randomized controlled trial : Clean version

    Journal of translational medicine

  4. Ergocalciferol improves physical function in humans.

    “Administration of vitamin D2 supplementation resulted in significant improvements in overall physical performance, including better outcomes in the balance test (p = 0.01), gait speed (p = 0.009), chair stand test (p < 0.001), and SPPB score (p < 0.001).”

    Human trial6 monthsn = 115

    Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease

    Clinical and translational science

  5. Ergocalciferol improves physical function in humans (p < 0.001).

    “Significant improvements were observed in muscle mass (p = 0.04), balance test (p = 0.01), gait speed (p = 0.009), chair stand test (p < 0.001), short physical performance (p < 0.001)”

    Human trial40,000 IU weekly6 monthsn = 115

    Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease

    Clinical and translational science

  6. Cholecalciferol showed no clear effect on physical function in humans.

    “Vitamin D3, omega-3s and SHEP had no effect on STS change across the 3-year follow-up.”

    Human trialthree-yearn = 2,157

    Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial

    The journal of nutrition, health & aging

  7. Vitamin D improves physical function in humans (idiopathic BPPV).

    “Participants who received vitamin D supplementation in group A had a better 5x sit to stand time compared to those in Group B as seen in Table.”

    Human trialidiopathic BPPV12 monthsn = 39

    Falls and physical function in older patients with Benign Paroxysmal Positional Vertigo (BPPV): findings from a placebo controlled, double blinded randomized control trial (RCT) investigating efficacy of vitamin D treatment in lowering the recurrence rate of BPPV

    Aging clinical and experimental research

  8. Vitamin D showed no clear effect on physical function in humans (idiopathic BPPV).

    “There was no evidence of a difference in SPPB scores at 6 or 12 months across all groups.”

    Human trialidiopathic BPPV12 monthsn = 53

    Falls and physical function in older patients with Benign Paroxysmal Positional Vertigo (BPPV): findings from a placebo controlled, double blinded randomized control trial (RCT) investigating efficacy of vitamin D treatment in lowering the recurrence rate of BPPV

    Aging clinical and experimental research

  9. Vitamin D showed no clear effect on physical function in humans.

    “No effects were seen on muscle strength or physical functioning.”

    Human trial20 weeksn = 40

    Vitamin D Status and Physical Functioning in Nursing Home Residents after Improved Adherence to the Vitamin D and Calcium Recommendation-A Quasiexperimental Study

    Journal of nutrition and metabolism

  10. Cholecalciferol showed no clear effect on physical function in humans.

    “There was no statistically significant interaction between treatment group and study time point for SPPB scores, grip strength, laying to standing systolic and diastolic blood pressure ratios, and ARR.”

    Human trial3 monthsfemalesn = 33

    Effects of High Dose Bolus Cholecalciferol on Free Vitamin D Metabolites, Bone Turnover Markers and Physical Function

    Nutrients

All 16

Inflammation

downin humans5downin mice3downin reviews3downin cells1+1

13 studies
  1. Vitamin D showed no clear effect on inflammation in overweight/obese vitamin D-deficient men.

    “there were no significant effects with vitamin D supplementation alone”

    Human trialin overweight/obese vitamin D-deficient men12 weeksmalesn = 48

    High-intensity Interval Training and Vitamin D Supplementation Improves Low-Grade Systemic Inflammation in Overweight/Obese Vitamin D-deficient men

    Research SquarePreprint

  2. Vitamin D decreases inflammation in humans (5000 IU daily compared with 1000 IU daily; IL-6 and TNF-α expression in PBMCs).

    “After the intervention, supplementation with D5N and D5 significantly downregulated p16, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) expression and decreased SA-β-gal activity compared to the D1 group.”

    Human trial5000 IU daily compared with 1000 IU daily; IL-6 and TNF-α expression in PBMCsperipheral blood mononuclear cells5000 IU daily8 weeks

    Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial

    Frontiers in immunology

  3. Calcitriol decreases inflammation in ovariectomized mice.

    “reducing pro-resorptive inflammatory signaling.”

    Animalsin ovariectomized mice

    Vitamin D mitigates Inflammatory Bone Loss in Postmenopausal Osteoporosis via modulating the Gut-Immune-Bone axis

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

  4. Vitamin D decreases inflammation in humans (SMD -0.40, 95% CI -0.48 to -0.32, p < 0.01).

    “vitamin D supplementation led to a decrease in inflammation (SMD: -0.40, 95% CI: -0.48 to -0.32, p < 0.01)”

    Review

    Effects of micronutrient supplementation on immune function in older adults: a meta-analysis

    Frontiers in immunology

  5. Vitamin D decreases inflammation in human models.

    “attenuation of vascular inflammation and fibrosis—effects validated in human models”

    Reviewin human models

    The vitamin D-cardiovascular nexus unraveling mechanistic promise and trial reality

    Nutrition & metabolism

  6. Vitamin D decreases inflammation in mice (fed a high-fat diet).

    “reduces body weight, blood lipid levels, and mild inflammation in older female mice”

    Animalsfed a high-fat dietfemales

    Vitamin D alleviates obesity-related metabolic abnormalities by modulating the gut microbiota in older female mice on a high-fat diet

    Frontiers in cellular and infection microbiology

  7. Calcitriol decreases inflammation in CVB3-induced acute viral myocarditis.

    “reduces AVMC inflammatory responses”

    Animalsin CVB3-induced acute viral myocarditis

    1,25-dihydroxyvitamin D deficiency accelerates inflammatory response by up-regulating inositol 1,4,5-triphosphate receptor in Coxsackievirus B3-induced acute myocarditis

    International immunopharmacology

  8. Vitamin D decreases inflammation.

    “Literature data reveal that vitamin D modulates gut microbiota diversity and composition, enhances immune resilience, and reduce systemic inflammation.”

    Review

    Gut-vitamin D interplay: key to mitigating immunosenescence and promoting healthy ageing

    Immunity & ageing : I & A

  9. Vitamin D decreases inflammation in humans (diabetic foot ulcer) (MD = -0.83, 95%CI -1.06 to -0.59, P < 0.01).

    “high sensitivity C-reactive protein (MD = -0.83, 95%CI -1.06 to -0.59, P < 0.01)”

    Reviewdiabetic foot ulcern = 580

    Effects of vitamin D supplementation on diabetic foot ulcer healing: a meta-analysis

    Postgraduate medical journal

  10. Vitamin D protects against inflammation in humans.

    “Vitamin D, in turn, protects the skin from oxidative stress, inflammation, and DNA damage, thereby delaying both chronological and photo-aging.”

    Review

    Impact of Vitamin D on Skin Aging, and Age-Related Dermatological Conditions

    Frontiers in bioscience (Landmark edition)

All 13

More on Inflammation

Cognitive function

upin humans10no changein humans2OR 0.77

12 studies
  1. Cholecalciferol improves cognitive function in humans (compared with placebo over 12 months).

    “all intervention groups demonstrated significant improvements in cognitive function and reductions in five blood biomarkers (IL-1β, IL-18, NLRP3, Gasdermin D (GSDMD), cleaved caspase-1) compared to the placebo group (p < 0.05)”

    Human trialcompared with placebo over 12 months800 IU/day12 months

    Effects of a Combined Vitamin D₃ and Docosahexaenoic Acid Intervention on Cognitive Function and Blood Pyroptotic Biomarkers in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial

    Nutrients

  2. Vitamin D showed no clear effect on cognitive function in humans (mild to moderate vitamin D deficiency and early cognitive impairment).

    “Vitamin D supplementation produced no measurable improvement in cognitive outcomes in older adults with mild to moderate vitamin D deficiency.”

    Human trialmild to moderate vitamin D deficiency and early cognitive impairment24-monthn = 620

    Impact of Vitamin D supplementation on cognition in adults with mild to moderate vitamin D deficiency: Outcomes from the VitaMIND randomised controlled trial

    AAIC 2025 abstract

  3. Cholecalciferol improves cognitive function in humans (vitamin D deficient).

    “Vitamin D replacement has a positive effect on cognitive domains related to visuospatial, executive, and memory processing functions.”

    Human trialvitamin D deficientvitamin D350 000 IU weekly for 8 weeks followed by 1000 U/day6 monthsfemalesn = 30

    The effect of vitamin D on neurocognitive functions in older vitamin D deficient adults: a pilot longitudinal interventional study

    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society

  4. Calcifediol is linked with better cognitive function in humans (β: 2.23; 95% CI: 0.88, 3.59).

    “serum 25(OH)D (β: 2.23; 95% CI: 0.88, 3.59) was positively associated with the Digit Symbol Substitution Test (DSST) score”

    Humansn = 2,858

    Blood micronutrients modified associations between blood heavy metals and cognitive decline in a nationally representative cross-sectional study

    The American journal of clinical nutrition

  5. Vitamin D is linked with better cognitive function in humans (overweight or obesity and metabolic syndrome) (β 1.18 × 10−2; 95% CI 0.19 × 10−2 to 2.17 × 10−2).

    “energy-adjusted cumulative average dietary vitamin D intake as a continuous variable was associated with greater 2-year improvements in global cognitive function (β 1.18 × 10−2; 95% CI 0.19 × 10−2 to 2.17 × 10−2)”

    Humansoverweight or obesity and metabolic syndrome2 yearsn = 5,454

    Dietary vitamin D intake and 2-year changes in cognitive function in older adults with overweight or obesity and metabolic syndrome

    GeroScience

  6. Vitamin D is linked with better cognitive function in humans (3rd tertile vs 1st tertile of intake) (OR: 0.77, 95% CI: 0.57-0.98).

    “individuals in the 3rd tertile of vitamin D intake (≥4.9 mcg/day) had significantly reduced odds of low performance on the CERAD test (OR: 0.77, 95% CI: 0.57-0.98; p = 0.031)”

    Humans3rd tertile vs 1st tertile of intake≥4.9 mcg/day vs ≤2.4 mcg/day

    Higher dietary vitamin D intake influences brain and mental function in elderly Americans: a cross-sectional analysis

    Frontiers in nutrition

  7. Vitamin D is linked with better cognitive function in humans (Mendelian randomization).

    “There is a causal relationship between vitamin D and cognitive performance”

    HumansMendelian randomization

    Vitamin D and Cognitive Performance in Older Adults: A Cross-Sectional and Mendelian Randomization Study

    Alpha psychiatry

  8. Cholecalciferol improves cognitive function in humans (SMD 0.66, 95% CI 0.02-1.30).

    “vitamin D significantly improved global cognition (SMD, 0.66; 95% CI, 0.02-1.30; P = .04)”

    Review

    Effects of Vitamin D Supplementation on Cognitive Function in Older Adults: A Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Methodology-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials

    Nutrition reviews

  9. Vitamin D showed no clear effect on cognitive function in humans (generally healthy older adults).

    “large randomized trials in generally healthy older adults, including VITAL and D-Health, report null effects”

    Reviewgenerally healthy older adults

    Neurobiological mechanisms linking vitamin d signaling to cognitive decline and neurodegeneration: Untangling epidemiology, pathophysiology, and evidence

    World journal of experimental medicine

  10. Vitamin D improves cognitive function in humans (particularly for those who are deficient).

    “Supplementation, particularly for those who are deficient, usually provides improvements resulting in moderate but meaningful improvement in mental health symptoms, neurodevelopmental outcomes, and cognitive function.”

    Reviewparticularly for those who are deficient

    Vitamin D and brain health: A systematic review

    Clinical Nutrition Open Science

All 12

Mortality

no changein humans6downin humans4downin silico1no changein silico1OR 0.51

11 studies
  1. Vitamin D showed no clear effect on mortality in humans (7.5% vs 10% at 6-month, 15% vs 12.5% at 1-year, 25% vs 27.5% at 2-year).

    “Mortality rate 6-month after the surgery was 7.5% and 10% for the intervention and placebo groups, respectively (P value =.71), 15% and 12.5% at 1-year (P value =.83), and 25% and 27.5% at 2-year (P value =.98).”

    Human trialampule intramuscularlyn = 80

    Adjuvant Vitamin D Injection in Elderly Patients Before Intertrochanteric Fracture Surgery: A Randomised Controlled Trial

    Geriatric orthopaedic surgery & rehabilitation

  2. Vitamin D showed no clear effect on mortality in patients with intertrochanteric fractures and a sufficient level of 25 (OH) VitD (7.5% vs 10% at 6 mo; 15% vs 12.5% at 1 yr; 25% vs 27.5% at 2 yr).

    “Mortality rate 6-month after the surgery was 7.5% and 10% for the intervention and placebo groups respectively (P value = .71), 15% and 12.5% at 1-year (P value = .83), and 25% and 27.5% at 2-year (P value = .98).”

    Human trialin patients with intertrochanteric fractures and a sufficient level of 25 (OH) VitDintramuscular ampule300,000 IUn = 80

    Adjuvant Vitamin D Injection in Elderly Patients Before Intertrochanteric Fracture Surgery: A Randomised Controlled Trial

    Geriatric orthopaedic surgery & rehabilitation

  3. Vitamin D was not clearly linked with mortality in multivariate model after hip fracture (OR 0.51; 95% CI 0.24-1.10).

    “in the multivariate model, this effect lost independent significance (OR 0.51; 95% CI 0.24-1.10; p=0.085)”

    Humansin multivariate model after hip fracture120 days

    In-hospital clinical and pharmacological determinants of 120-day mortality and institutionalization after hip fracture: functional and pharmacological implications in Primary Care

    Semergen

  4. Vitamin D showed no clear effect on mortality in humans (General population, including patients with low baseline serum 25-hydroxyvitamin D).

    “do not demonstrate reduced all-cause mortality or improvement in cardiovascular health.”

    ReviewGeneral population, including patients with low baseline serum 25-hydroxyvitamin D

    Vitamin D Supplementation in Community-Dwelling Adults

    American family physician

  5. Vitamin D decreases mortality in humans (specific populations).

    “selected benefits have been reported in specific populations, including mortality reduction in adults aged ≥ 75 years”

    Reviewspecific populations

    From the Vitamin D Paradox to Precision Nutrition: Targeted Supplementation, Assay Pitfalls, and Clinical Decision-Making

    Current nutrition reports

  6. Vitamin D decreases mortality in humans (threshold-dependent).

    “reductions in cancer mortality, protection against autoimmune disorders, most convincingly multiple sclerosis, and decreased risk of acute respiratory infections, including COVID-19”

    Reviewthreshold-dependent

    Vitamin D and Health Outcomes: State-of-the-Art Review of Triangulated Evidence and Ongoing Controversies

    Current nutrition reports

  7. Vitamin D decreases mortality in silico (restricted to people with vitamin D insufficiency) (HR 0.85 [95% CI: 0.79-0.91]).

    “major mortality reduction was expected in emulated trials that were restricted to people with vitamin insufficiency (HR 0.85 [95%CI: 0.79-0.91] and 0.81 [95%CI: 0.76-0.86])”

    In silicorestricted to people with vitamin D insufficiency

    Impact of vitamin D supplementation on all-cause mortality: Randomized trials revisited

    Clinical nutrition (Edinburgh, Scotland)

  8. Vitamin D showed no clear effect on mortality in silico (weighted to 25(OH)D distributions of original trials (vitamin D sufficient)) (HR 0.97 [95 % CI: 0.92-1.02]).

    “Emulated trials with study populations weighted to the 25(OH)D distributions of the original trials yielded null results similar to those reported (hazard ratios [HR] 0.97 [95 % CI: 0.92-1.02]”

    In silicoweighted to 25(OH)D distributions of original trials (vitamin D sufficient)5.3 years

    Impact of vitamin D supplementation on all-cause mortality: Randomized trials revisited

    Clinical nutrition (Edinburgh, Scotland)

  9. Vitamin D showed no clear effect on mortality in humans (RR = 1.04, 95%CI: 0.871-1.242).

    “CVD mortality (RR = 1.04, 95%CI: 0.871-1.242)”

    Review

    Vitamin D supplementation and cardiovascular disease events: a systematic review and pooled meta-analysis of randomized clinical trials

    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

  10. Vitamin D showed no clear effect on mortality in humans (RR 1.04, 95% CI 0.83 to 1.31).

    “Regarding vitamin D supplementation, seven studies (2600 participants) reported all-cause mortality (pooled RR: 1.04, 95% CI: 0.83 to 1.31, I2 = 35%)”

    Reviewn = 2,600

    Micronutrient Supplementation in Frailty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Healthcare (Basel, Switzerland)

All 13

Handgrip strength

upin humans6no changein humans3

9 studies
  1. Cholecalciferol showed no clear effect on handgrip strength in vitamin D-deficient hemodialysis patients with 25OHD ≤50 nmol/L (0.07 ± 3.40 kg (cholecalciferol) and -0.19 ± 3.35 kg (control), P = .682).

    “HGS did not change significantly between randomization and end of the study in both groups”

    Human trialin vitamin D-deficient hemodialysis patients with 25OHD ≤50 nmol/L100 000 IU monthly oral6 monthsn = 143

    Cholecalciferol and muscle strength in hemodialysis patients: results from the randomized VITADIAL trial

    Clinical kidney journal

  2. Cholecalciferol improves handgrip strength in humans.

    “The WT group showed greater handgrip strength than the control group (p < 0.001), and the D group also showed improvement over the control group (p = 0.001).”

    Human trial8 weeksfemalesn = 44

    Vitamin D3 supplementation enhances the effect of aerobic water-based training on physical fitness indices in obese and overweight menopausal women: A randomized controlled trial

    Women's health (London, England)

  3. Vitamin D improves handgrip strength in humans.

    “It improved significantly at 6 and 12 months, similarly in men and women, and especially in prefrail and frail patients and patients with sarcopenia.”

    Human trial12 monthsn = 39

    Treatment of Vitamin D Deficiency in Decompensated Patients with Cirrhosis Is Associated with Improvement in Frailty

    Medical sciences (Basel, Switzerland)

  4. Vitamin D improves handgrip strength in humans (decompensated cirrhosis and vitamin D deficiency or insufficiency) (p = 0.001 at 6 months, p = 0.002 at 12 months).

    “handgrip strength improved at 6 (p = 0.001) and 12 (p = 0.002) months, similarly in women and men”

    Human trialdecompensated cirrhosis and vitamin D deficiency or insufficiency6 to 12 months

    Treatment of Vitamin D Deficiency in Decompensated Patients with Cirrhosis Is Associated with Improvement in Frailty

    Medical sciences (Basel, Switzerland)

  5. Vitamin D improves handgrip strength in humans.

    “Both groups exhibited significant improvements in skeletal muscle mass, handgrip strength and glucose/lipid metabolism post-treatment, with the treatment group demonstrating superior enhancements (P<0.05).”

    Human trialcombined with thermotherapy and resistance exercise, compared with thermotherapy and resistance exercise alone, in sarcopenia patientsn = 140

    The effects of vitamin D combined with thermotherapy and resistance exercise on inflammatory factors, thyroid hormones and MSTN in elderly patients with sarcopenia

    Pakistan journal of pharmaceutical sciences

  6. Vitamin D is linked with better handgrip strength in humans (vitamin D deficiency) (+16.2% vs no change).

    “the supplementation group showed a 16.2% increase in the HGS versus no change in the comparison group (p < 0.001; ANCOVA partial η2 = 0.284)”

    Humansvitamin D deficiency12 monthsn = 164

    Vitamin D Supplementation and 12-Month Changes in Muscle Function and Physical Performance in Older Adults with Vitamin D Deficiency: A Prospective Observational Cohort Study

    Nutrients

  7. Vitamin D improves handgrip strength in humans (combined with exercise versus exercise-only).

    “Additionally, handgrip strength improved significantly in older adults and in those receiving higher vitamin D doses.”

    Reviewcombined with exercise versus exercise-only

    Effects of Vitamin D Supplementation in Combination With Exercise Training on Body Composition and Muscular Strength in Adults: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials

    Nutrition reviews

  8. Vitamin D showed no clear effect on handgrip strength in humans.

    “The vitamin D intake group was not associated with an increase in SMI, LM, or handgrip strength compared to the control group”

    Review

    Effects of vitamin D intake alone on elderly body composition: A systematic review and meta-analysis of RCTs

    Archives of gerontology and geriatrics

  9. Vitamin D showed no clear effect on handgrip strength in humans (p = .26).

    “Regarding muscle strength, vitamin D supplementation did not have a significant effect on muscle strength which is handgrip strength (p = .26).”

    Review

    The Effect of Vitamin D Supplementation to Parameter of Sarcopenia in Elderly People: a Systematic Review and Meta-Analysis

    Canadian geriatrics journal : CGJ

  10. Vitamin D improves handgrip strength in humans (menopausal women) (SMD = 0.303, 95% CI: 0.130, 0.476).

    “Vitamin D supplementation improved handgrip strength (SMD = 0.303, 95% CI: 0.130, 0.476), but not knee extension strength.”

    Reviewmenopausal womenfemalesn = 1,989

    Effect of non-pharmacological interventions on the prevention of sarcopenia in menopausal women: a systematic review and meta-analysis of randomized controlled trials

    BMC women's health

Falls

no changein humans7downin humans2RR 0.87–1.03

9 studies
  1. Vitamin D was not clearly linked with falls in humans (IRR 1.01, 95% CI 1.00-1.02, P = 0.237).

    “no significant links were observed between vitamin D supplement usage and fall outcomes: all falls (Incident Rate Ratio [IRR] 1.01; 95 % CI 1.00-1.02; P = 0.237)”

    Humans36 monthsn = 4,520

    Vitamin D supplementation and falls in residential aged care: A longitudinal multisite cohort study

    Bone reports

  2. Vitamin D decreases falls in humans (reduced falls by 13% (RR 0.87)).

    “Vitamin D supplementation (≥700 IU/day) reduced falls by 13% (risk ratio [RR] 0.87, moderate certainty)”

    Review≥700 IU/day

    Exercise and nutritional interventions for sarcopenia-related fall prevention in older adults: An umbrella review

    The journal of nutrition, health & aging

  3. Cholecalciferol showed no clear effect on falls in humans.

    “mega-trials established that vitamin D supplementation with the equivalent of 2000 to 3300 IU/d of vitamin D3 had no favorable effect on risk of falls or fractures”

    Reviewvitamin D32000 to 3300 IU/dn = 50,000

    Effect of vitamin D on risk of falls and fractures - The contribution of recent mega-trials

    Metabolism open

  4. Vitamin D showed no clear effect on falls in humans (RR 1.01; 95% CI 0.97-1.04; p = 0.66).

    “There was no significant difference in non-vertebral fractures, osteoporotic fractures development, or falls”

    Reviewhealthy individuals without bone related medical conditions such as cancer and osteoporosis

    Vitamin D Supplementation and the Incidence of Fractures in the Elderly Healthy Population: A Meta-analysis of Randomized Controlled Trials

    Journal of general internal medicine

  5. Cholecalciferol showed no clear effect on falls in humans (RR 1.02, 95% CI 0.98-1.05).

    “Likewise, it did not significantly reduce the risks of falls and fractures, with risk ratios of 1.02 (0.98-1.05) and 0.95 (0.87-1.04) respectively.”

    Reviewintermittent monthlyover 800 IU per day

    Effects of intermittent overload doses of oral vitamin D3 on serum 25(OH)D concentrations and the incidence rates of fractures, falls, and mortality in elderly individuals: A systematic review and meta-analysis

    Biomolecules & biomedicine

  6. Vitamin D decreases falls in community-dwelling populations.

    “'Vitamin D' interventions may be beneficial in community-dwelling populations but not in RAC settings.”

    Reviewin community-dwelling populations

    Effectiveness of fall prevention interventions in residential aged care and community settings: an umbrella review

    BMC geriatrics

  7. Vitamin D showed no clear effect on falls in humans (OR 1.01, 95% CI 0.92-1.11, p=0.86).

    “vitamin D supplementation decreased the odds of having at least one fall by 1% (odds ratio [OR]=1.01; 95% confidence interval [CI], 0.92-1.11; p=0.86); however, the difference was not statistically significant”

    Reviewn = 38,598

    Effectiveness of Vitamin D Supplements in Reducing the Risk of Falls among Older Adults: A Meta-Analysis of Randomized Controlled Trials

    Annals of geriatric medicine and research

  8. Vitamin D showed no clear effect on falls in humans (generally healthy adults).

    “These studies found no benefit of 2 000 IU/d of supplemental vitamin D on nonvertebral fractures, falls, functional decline, or frailty.”

    Reviewgenerally healthy adults2 000 IU/d

    The Effects of Vitamin D Supplementation on Musculoskeletal Health: The VITAL and DO-Health Trials

    The journals of gerontology. Series A, Biological sciences and medical sciences

  9. Vitamin D showed no clear effect on falls in humans (RR 1.03, 95% CI 0.98-1.09).

    “intermittent or single high-dose vitamin D supplementation showed no significant beneficial effect in the prevention of either falls (RR, 1.03 [95% CI, 0.98-1.09]; I2 = 56.6%; n = 11)”

    Reviewintermittent or single high-dose

    Effects of intermittent or single high-dose vitamin D supplementation on risk of falls and fractures: a systematic review and meta-analysis

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Fasting blood glucose

downin humans7no changein humans1

8 studies
  1. Cholecalciferol decreases fasting blood glucose in humans (112.6 ± 8.4 to 102.4 ± 7.3 mg/dL; greater improvement than controls, P < 0.001).

    “The Vitamin D group demonstrated significant reductions in FBG (112.6 ± 8.4-102.4 ± 7.3 mg/dL)”

    Human trialAdults with prediabetes; supplementation plus lifestyle advice compared with lifestyle advice alone2000 IU once daily3 monthsn = 90

    Effects of Vitamin D 3 Supplementation on Glycaemic Parameters and Insulin Sensitivity in Pre-diabetic Adults: A Prospective Controlled Interventional Study

    The Nigerian postgraduate medical journal

  2. Vitamin D decreases fasting blood glucose in humans.

    “Our NMA of 21 RCTs suggested that, compared with control, LDS decreased fasting blood glucose (FBG) and was ranked as the most effective in decreasing FBG (surface under the cumulative ranking curve = 87.9%).”

    Human trial

    Effects of Vitamin D Supplemental Dose in Adults with Prediabetes: A Systematic Review and Network Meta-Analysis

    Nutrition reviews

  3. Cholecalciferol decreases fasting blood glucose in humans (cosupplementation with flaxseed oil in elderly patients with T2DM) (MD: -22.83 mg/dL).

    “reductions were observed in weight (MD: -1.73 kg, p < 0.001), BMI (MD: -0.67 kg/m2, p < 0.001), fasting blood glucose (MD: -22.83 mg/dL, p = 0.015)”

    Human trialcosupplementation with flaxseed oil in elderly patients with T2DM50,000 IU every two weeks vitamin D3 + 500 mg TID flaxseed oil8 weeksn = 104

    An 8-Week Triple-Blind, Randomized, Placebo-Controlled Trial Evaluating High-Dose Vitamin D3 and Flaxseed Oil for Inflammation and Metabolic Health in Elderly Patients With Type 2 Diabetes: Implications for Clinical Management

    Journal of nutrition and metabolism

  4. Cholecalciferol showed no clear effect on fasting blood glucose in humans (postmenopausal women with T2DM) (median of 120 mg/dL at baseline and 110 mg/dL after cholecalciferol supplementation, p = 0.059).

    “fasting blood glucose values showed a median of 120 mg/dL at baseline and 110 mg/dL after cholecalciferol supplementation”

    Human trialpostmenopausal women with T2DM1000 IU/day for 12 months, followed by 2000 IU/day for another 12 months24 monthsfemalesn = 34

    Long-Term Cholecalciferol Supplementation and Metabolic Parameters in Postmenopausal Women with Type 2 Diabetes Mellitus: A Longitudinal Prospective Study

    Diabetology

  5. Vitamin D decreases fasting blood glucose in humans (-0.11 (95%CI:-0.185, -0.036)).

    “fasting blood glucose by -0.11 (95%CI:-0.185, -0.036)”

    Review

    Does Vitamin D Supplementation Modulate Metabolic Risk Factors of Cardiovascular Disease? A Systematic Review and Meta-Analysis of Clinical Trials

    medRxivPreprint

  6. Vitamin D decreases fasting blood glucose in gestational diabetes mellitus (SMD -1.01, p = 0.0002).

    “vitamin D supplementation significantly reduced fasting glucose (SMD: -1.01, p = 0.0002)”

    Reviewin gestational diabetes mellitus

    Effects of vitamin D supplementation on glucose metabolism and pregnancy outcomes in GDM: a systematic review and meta-analysis

    Frontiers in medicine

  7. Vitamin D decreases fasting blood glucose in humans (polycystic ovary syndrome) (MD -2.91 mg/dL, 95% CI (-4.78, -1.04) mg/dL).

    “supplementation of vitamin D led to a notable reduction in the subsequent metabolic parameters: fasting blood glucose[MD=-2.91 mg/dL, 95% CI (-4.78, -1.04) mg/dL, P = 0.002]”

    Reviewpolycystic ovary syndrome

    The impact of vitamin D supplementation on glycemic control and lipid metabolism in polycystic ovary syndrome: a systematic review of randomized controlled trials

    BMC endocrine disorders

  8. Vitamin D decreases fasting blood glucose in humans (postmenopausal women) (WMD -3.56 mg/dL; 95% CI -5.49 to -1.64).

    “An overall decrease was noted in fasting blood glucose (weighted mean difference [WMD], -3.56 mg/dL; 95% CI, -5.49 to -1.64; P < 0.001)”

    Reviewpostmenopausal womenfemales

    The Effects of Vitamin D on Markers of Glucose and Obesity in Postmenopausal Women: A Meta-analysis of Randomized Controlled Trials

    Clinical therapeutics

More on Fasting blood glucose

Muscle strength

upin humans3no changein humans2upin mice1upin rats1+1

8 studies
  1. Vitamin D showed no clear effect on muscle strength in humans.

    “Muscle strength gains (p < 0.001) as measured in seven exercises performed on RT equipment and increases (p < 0.001) in LBM were similar in the two groups.”

    Human trialVitamin D-insufficient healthy men participating in resistance training; compared with placebo8000 IU daily12 weeksmalesn = 28

    Vitamin D Supplementation Does Not Enhance Gains in Muscle Strength and Lean Body Mass or Influence Cardiorespiratory Fitness in Vitamin D-Insufficient Middle-Aged Men Engaged in Resistance Training

    Nutrients

  2. Calcifediol was not clearly linked with muscle strength in humans (p-trend = 0.140).

    “no association was observed in older women (p-trend = 0.140)”

    Humansfemalesn = 543

    Sex-dependent association of serum vitamin D with muscle strength in older adults: NHANES 2001-2002

    European journal of clinical nutrition

  3. Vitamin D improves muscle strength in humans (menopause).

    “Vitamin D demonstrates crucial importance for bone health and muscle strength in postmenopausal women, with a minimum dose of 800 IU/day required to achieve sufficient levels.”

    Reviewmenopause800 IU/dayfemales

    Role of vitamins in the management of the climacteric and menopause

    Revista Hospital Clínico Universidad de Chile

  4. Vitamin D improves muscle strength in humans.

    “Consequently, vitamin D supplementation can improve muscle strength, balance, and physical performance”

    Reviewskeletal musclefemales

    Vitamin D as a Modulator of Sarcopenia in Women: Interactions with Dietary Patterns and Physical Exercise

    Nutrients

  5. Cholecalciferol improves muscle strength in rats (aged diabetic rats).

    “whereas vitamin D3 supplementation improved muscle strength, myofiber cross-sectional area, and lipid infiltration.”

    Animalsaged diabetic ratsgastrocnemius muscle2000 IU

    Vitamin D status and sarcopenia in older adults: population-based evidence for synergy with diabetes and experimental validation in an aged diabetic rat model

    The journal of nutrition, health & aging

  6. Vitamin D improves muscle strength in humans.

    “improved muscle function (chair rising test, hip extensor/adductor strength)”

    Reviewfemalesn = 3,054

    A systematic review on the effect of vitamin D supplementation in bone mineral density and muscle strength in postmenopausal women

    International journal of Nutrition Pharmacology Neurological Diseases

  7. Vitamin D improves muscle strength.

    “benefits of vitamin D on the muscular system are comparable to those of physical activity in terms of shaping the structural and functional changes in muscles”

    Review

    Vitamin D and physical activity as co-modifiers of muscle health and function - a narrative exploration

    Annals of medicine and surgery (2012)

  8. Cholecalciferol improves muscle strength in mice (aged mice on vitamin D3-supplemented diet).

    “the reduction in muscle strength and mass due to aging was reversed by vitamin D3 supplementation”

    Animalsaged mice on vitamin D3-supplemented dietdietary supplement20,000 IU/kg diet4 months

    Activation of the apelin/APJ system by vitamin D attenuates age-related muscle atrophy

    Life sciences

Grip strength

no changein humans3upin humans3upin mice2

7 studies
  1. Ergocalciferol showed no clear effect on grip strength in humans (between fixed-dose and severity-dependent groups) (P > .05).

    “Muscle strength, gait speed, and serum insulin-like growth factor-1 level, as the mediators of muscle cell growth, were not different between the two groups at 6 months (P > .05).”

    Human trialbetween fixed-dose and severity-dependent groups6 months

    A Comparison Between Severity-Dependent Protocol and Fixed-Dose Regimen of Oral Vitamin D Supplementation on Correction of Hypovitaminosis D Among Dialysis Patients

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  2. Vitamin D is linked with better grip strength in humans.

    “The study also showed that the grip strength and pinch strength of the patients in both groups increased after the intervention, and the difference between the two groups was statistically significant (p < 0.05).”

    Humans9 months

    Effects of vitamin D supplementation on muscle strength in middle-aged and elderly individuals: a retrospective, propensity score-matched study

    Frontiers in nutrition

  3. Vitamin D is linked with better grip strength in conjunction with lifestyle guidance and health education (p<0.05).

    “the grip strength and pinch strength of the patients in both groups increased after the intervention, and the difference between the two groups was statistically significant (p<0.05).”

    Humansin conjunction with lifestyle guidance and health educationoral

    Effects of vitamin D supplementation on muscle strength in middle-aged and elderly individuals: a retrospective, propensity score-matched study

    Frontiers in nutrition

  4. Vitamin D was not clearly linked with grip strength in humans (osteoporosis, residing in long-term care facilities) (r = -0.05, p = 0.4686).

    “(r = - 0.05; p = 0.4686)”

    Humansosteoporosis, residing in long-term care facilitiesfemalesn = 246

    The association of vitamin D with bone microarchitecture, muscle strength, and mobility performance in older women in long-term care

    Bone

  5. Vitamin D is linked with better grip strength in humans (0.11 kg (95% CI 0.04, 0.19)).

    “linear MR analyses for grip strength showing 0.11 kg (95% CI 0.04, 0.19) greater contractile force per 10 unit higher 25(OH)D”

    Humansper 10 unit higher 25(OH)D

    Muscle Traits, Sarcopenia, and Sarcopenic Obesity: A Vitamin D Mendelian Randomization Study

    Nutrients

  6. Calcitriol increases grip strength in mice (sarcopenic obesity mouse model).

    “as evidenced by increased grip strength, enhanced behavioral activity”

    Animalssarcopenic obesity mouse model

    Targeting the mTOR-mitochondrial function axis: Calcitriol attenuates sarcopenic obesity with lipid dysregulation etiology

    Free radical biology & medicine

  7. Vitamin D improves grip strength in mice.

    “Animal studies, primarily in mice, demonstrate vitamin D's positive effects on skeletal muscle function, such as improved grip strength and endurance.”

    Reviewin mice

    The Role of Vitamin D in Skeletal Muscle Repair and Regeneration in Animal Models and Humans: A Systematic Review

    Nutrients

  8. Vitamin D improves grip strength in humans (co-supplementation with protein in sarcopenic individuals) (9.8-40.5%).

    “vitamin D 100-1,000 IU/day co-supplementation with protein results in increased handgrip strength between 9.8-40.5%”

    Reviewco-supplementation with protein in sarcopenic individuals100-1,000 IU/day

    Current Research on Vitamin D Supplementation against Sarcopenia: A Review of Clinical Trials

    International journal of sports medicine

  9. Vitamin D showed no clear effect on grip strength in humans.

    “without improving handgrip strength or muscle mass”

    Review880-1600 IU/day

    Current Research on Vitamin D Supplementation against Sarcopenia: A Review of Clinical Trials

    International journal of sports medicine

C-reactive protein

downin humans4no changein humans2

6 studies
  1. Cholecalciferol decreases C-reactive protein in humans (cosupplementation with flaxseed oil in elderly patients with T2DM) (MD: -0.98 μg/mL).

    “The primary outcome, serum hs-CRP, was significantly reduced in the intervention group compared to controls (MD: -0.98 μg/mL, p = 0.034).”

    Human trialcosupplementation with flaxseed oil in elderly patients with T2DM50,000 IU every two weeks vitamin D3 + 500 mg TID flaxseed oil8 weeksn = 104

    An 8-Week Triple-Blind, Randomized, Placebo-Controlled Trial Evaluating High-Dose Vitamin D3 and Flaxseed Oil for Inflammation and Metabolic Health in Elderly Patients With Type 2 Diabetes: Implications for Clinical Management

    Journal of nutrition and metabolism

  2. Cholecalciferol decreases C-reactive protein in adult epilepsy patients treated with enzymatic antiseizure medications (–6.74 ± 14.65 vs. 1.81 ± 7.75 mg/L).

    “significantly greater reduction in hs-CRP (–6.74 ± 14.65 vs. 1.81 ± 7.75 mg/L; p = 0.041) compared with placebo”

    Human trialin adult epilepsy patients treated with enzymatic antiseizure medications2,000 IU/day12 weeks

    Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial

    Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina

  3. Cholecalciferol decreases C-reactive protein in humans (3.28 ± 2.02 versus 3.64 ± 2.42 mg/L).

    “the hs-CRP levels were significantly lower (3.28 ± 2.02 VS 3.64 ± 2.42 mg/L).”

    Human trialPregnant women with serum 25(OH)D <75 nmol/L; supplementation started at 24–28 weeks' gestation1600 IU/day versus 400 IU/day2 monthsfemalesn = 1,537

    Vitamin D supplementation for cardiometabolic risk markers in pregnant women based on the gestational diabetes mellitus or obesity status : a randomized clinical trial

    European journal of nutrition

  4. Vitamin D was not clearly linked with C-reactive protein in humans (obesity).

    “No significant association was found between vitamin D intake and CRP levels”

    Humansobesityn = 70

    THE RELATIONSHIP BETWEEN VITAMIN D INTAKE AND PLASMA C-REACTIVE PROTEIN LEVELS AND APPENDICULAR SKELETAL MUSCLE INDEX IN ADULTS WITH OBESITY

    SOSIOEDUKASI JURNAL ILMIAH ILMU PENDIDIKAN DAN SOSIAL

  5. Calcifediol is linked with lower C-reactive protein in humans (at baseline, cross-sectional comparison).

    “individuals with higher blood 25(OH)D concentrations had lower levels of glucose, glycohemoglobin, CRP, and insulin”

    Humansat baseline, cross-sectional comparisonn = 2,916

    Association of serum 25-hydroxyvitamin D concentrations with all-cause mortality among individuals with kidney stone disease: the NHANES database prospective cohort study

    Frontiers in endocrinology

  6. Vitamin D showed no clear effect on C-reactive protein in humans (Overweight or obesity, vitamin D deficiency, and no comorbidities) (MD 0.01; 95% CI -0.37 to 0.39).

    “The VitD supplementation did not influence C-reactive protein”

    ReviewOverweight or obesity, vitamin D deficiency, and no comorbiditiesDaily 1000–7000 international units or bolus 100,000–200,000 international units2 to 26 weeksn = 504

    Vitamin D supplementation does not alter inflammatory markers in overweight and obese individuals: A systematic review and meta-analysis of randomized controlled trials

    Nutrition research (New York, N.Y.)

More on C-reactive protein

Vitamin D

upin humans6+85% insufficiency

6 studies
  1. Vitamin D increases vitamin D in humans (vitamin D insufficiency) (p<0.05).

    “After 12 weeks, the intervention group showed significant improvements in serum vitamin D levels and neuromuscular performance compared with placebo.”

    Human trialvitamin D insufficiency60,000 IU weekly12 weeksn = 60

    Vitamin D supplementation enhances neuromuscular function in older adults: controlled clinical trial

    Geriatric Care

  2. Vitamin D increases vitamin D in humans (66.6 ± 31.7 nmol/L to 82.8 ± 26.3 nmol/L).

    “mean vitamin D status increased from 66.6 ± 31.7 nmol/L to 82.8 ± 26.3 nmol/L (P < 0.001)”

    Human trial20 weeksn = 30

    Vitamin D Status and Physical Functioning in Nursing Home Residents after Improved Adherence to the Vitamin D and Calcium Recommendation-A Quasiexperimental Study

    Journal of nutrition and metabolism

  3. Cholecalciferol increases vitamin D in humans (chronic spinal cord injury and vitamin D deficiency) (P = 0.038).

    “Group B significantly increased vitamin D (P = 0.038) and protein mass (PM) (P = 0.034) levels.”

    Human trialchronic spinal cord injury and vitamin D deficiency800 IU/day12 weeksn = 9

    Age-dependent effect of vitamin D supplementation on musculoskeletal health in chronic spinal cord injury patients: A pilot study

    The journal of spinal cord medicine

  4. Vitamin D is linked with higher vitamin D in humans.

    “indicating a significant relationship between higher egg and/or vitamin D supplement intake and increased blood vitamin D levels.”

    Humansfemalesn = 57

    Vitamin D Deficiency in Elderly Postmenopausal Women: The Role of Sunlight, Diet, and Vitamin D Status

    Jurnal Kesehatan Masyarakat

  5. Vitamin D is linked with higher vitamin D in humans (adult children of patients with low-energy proximal femur fractures) (85% insufficiency).

    “Vitamin D insufficiency was present in 85%, with supplementation associated with higher serum concentrations.”

    Humansadult children of patients with low-energy proximal femur fracturesn = 60

    Early detection of osteoporosis in adult children of patients with proximal femur fractures: a real-world screening study

    BMC musculoskeletal disorders

  6. Vitamin D increases vitamin D in humans.

    “Supplementation significantly increased vitamin D levels”

    Reviewfemalesn = 3,054

    A systematic review on the effect of vitamin D supplementation in bone mineral density and muscle strength in postmenopausal women

    International journal of Nutrition Pharmacology Neurological Diseases

More on Vitamin D

HOMA-IR

downin humans3no changein humans2

5 studies
  1. Vitamin D decreases HOMA-IR in humans (compared with low dosing strategy) (MD = −2.82; 95% CI, –5.06 to −0.57).

    “And EHDS (MD = −2.82; 95% CI, –5.06 to −0.57) was more efficacious than LDS in reducing the homeostasis model assessment for insulin resistance (HOMA-IR) value.”

    Human trialcompared with low dosing strategy

    Effects of Vitamin D Supplemental Dose in Adults with Prediabetes: A Systematic Review and Network Meta-Analysis

    Nutrition reviews

  2. Vitamin D decreases HOMA-IR in humans (prediabetes) (MD = -2.82, 95% CI -5.06 to -0.57).

    “And EHDS (MD = -2.82; 95% CI, -5.06 to -0.57) was more efficacious than LDS in reducing the homeostasis model assessment for insulin resistance (HOMA-IR) value.”

    Human trialprediabetes≥4000 IU d-1 vs <1000 IU d-1

    Effects of Vitamin D Supplemental Dose in Adults with Prediabetes: A Systematic Review and Network Meta-Analysis

    Nutrition reviews

  3. Cholecalciferol showed no clear effect on HOMA-IR in adult epilepsy patients treated with enzymatic antiseizure medications (–0.24 ± 3.71 vs. –0.14 ± 3.38).

    “no significant differences were observed between groups regarding the changes in HOMA-IR (–0.24 ± 3.71 vs. –0.14 ± 3.38; p = 0.940)”

    Human trialin adult epilepsy patients treated with enzymatic antiseizure medications2,000 IU/day12 weeks

    Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial

    Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina

  4. Cholecalciferol showed no clear effect on HOMA-IR in humans (polycystic ovary syndrome).

    “Overall, we observed no substantial HOMA-IR improvement with vitamin D subjunction.”

    Human trialpolycystic ovary syndrome2000 IU/day3 monthsfemales

    Polycystic Ovary Syndrome and Vitamin D Status - Impact of Vitamin D Supplementation on Insulin Resistance

    Reviews on recent clinical trials

  5. Vitamin D decreases HOMA-IR in women with PCOS.

    “The BMI, WHR, insulin concentrations, homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations in women of Vitamin D group after 12 weeks of treatment were significantly lower than that in women of control group (P < 0.05).”

    Human trialin women with PCOS2000 IU/day12 weeksfemalesn = 60

    Effects of vitamin D supplementation on metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial

    Journal of ovarian research

  6. Vitamin D decreases HOMA-IR in male patients with schizophrenia and vitamin D deficiency (P = .014).

    “The between-group comparison showed a significant difference in terms of PANSS-TS, GSK-3β, fasting serum insulin (FSI), and HOMA-IR (P = .022, P = .048, P = .013 and P = .014 respectively).”

    Human trialin male patients with schizophrenia and vitamin D deficiencyserum2000 IU/day8 weeksmalesn = 48

    A randomized controlled trial of Vitamin D supplementation in Iranian patients with schizophrenia: Effects on serum levels of glycogen synthase kinase-3β and symptom severity

    International journal of psychiatry in medicine

More on HOMA-IR

Parathyroid hormone

downin humans5

5 studies
  1. Cholecalciferol decreases parathyroid hormone in humans (vitamin D deficiency).

    “Both groups showed significant increases in serum 25(OH)D levels and reductions in PTH from baseline.”

    Human trialvitamin D deficiencyoral10 weeksn = 50

    Efficacy and safety of oral versus high dose intramuscular vitamin D therapy in elderly patients: A randomized controlled study

    Indian Journal of Orthopaedics Surgery

  2. Calcitriol decreases parathyroid hormone in humans (hip osteoporotic fractures and vitamin D deficiency).

    “however, PTH1−84 decreased after the treatment.”

    Human trialhip osteoporotic fractures and vitamin D deficiencyintravenousserum2 μg/daytwo weeksfemales

    Calcitriol Modulates Both the Vitamin D Receptor and the Calcium-Sensing Receptor in Blood Mononuclear Cells in Elderly Female Patients with Hip Osteoporotic Fractures

    Biomolecules

  3. Calcifediol decreases parathyroid hormone in humans (post-hip fracture surgery) (43.5 vs. 75.2 pg/mL, p = 0.001).

    “PTH decreased more in the IG (43.5 vs. 75.2 pg/mL; p = 0.001).”

    Human trialpost-hip fracture surgery266 μg daily for 5 days vs. 266 μg weekly for 5 weeksn = 50

    Efficacy of two calcifediol supplementation regimens in older adults post-hip fracture surgery. A clinical trial

    European geriatric medicine

  4. Ergocalciferol decreases parathyroid hormone in humans.

    “Furthermore, plasma PTH levels showed a significant decrease (p < 0.001) following the supplementation.”

    Human trial6 monthsn = 115

    Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease

    Clinical and translational science

  5. Ergocalciferol decreases parathyroid hormone in humans (p < 0.001).

    “with a significant reduction in PTH (p < 0.001).”

    Human trial40,000 IU weekly6 monthsn = 115

    Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease

    Clinical and translational science

  6. Cholecalciferol decreases parathyroid hormone in humans (vitamin D insufficiency; especially higher baseline serum PTH).

    “Serum PTH decreased during the first 6 weeks, after which it entered a plateau, especially in the group with higher baseline serum PTH.”

    Human trialvitamin D insufficiency; especially higher baseline serum PTHserum400 or 800 IU/dayfirst 6 weeksfemales

    Assessment of the effect of routine-dose vitamin D3 supplementation in Chinese women of childbearing age with vitamin D insufficiency

    European journal of nutrition

More on Parathyroid hormone

Blood pressure

no changein humans2downin humans2downin mice1

5 studies
  1. Vitamin D showed no clear effect on blood pressure in conflict-exposed adults.

    “with no treatment-specific effect on blood pressure or HbA1c.”

    Human trialin conflict-exposed adultsthree 200,000 IU doses, 4-week intervalsn = 125

    Sunshine Against Stress: A Randomised, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation for Allostatic Load in a Conflict-Affected Population of Azad Jammu & Kashmir

    Preprints.orgPreprint

  2. Vitamin D decreases blood pressure in elderly patients with H-type hypertension.

    “While the former group had lower levels of 24 hours SBP, 24 hours DBP, dSBP, dDBP, nSBP, and nDBP than the latter group (p< 0.05, ).”

    Human trialin elderly patients with H-type hypertension12 weeks

    Efficacy of Vitamin-D supplementation in improving the prognosis of H-type hypertension in elderly patients

    Pakistan journal of medical sciences

  3. Cholecalciferol showed no clear effect on blood pressure in humans (vitamin D deficient postmenopausal women).

    “Treatment did not affect serum calcium, postural blood pressure, ARR, or physical function.”

    Human trialvitamin D deficient postmenopausal women

    Effects of High Dose Bolus Cholecalciferol on Free Vitamin D Metabolites, Bone Turnover Markers and Physical Function

    Nutrients

  4. Calcifediol is linked with lower blood pressure in humans (-1.07 mmHg SBP, -1.19 mmHg DBP, -1.22 mmHg MAP per 10 ng/mL).

    “Each 10 ng/mL increase in serum 25(OH)D was associated with a 1.07 mmHg lower SBP, a 1.19 mmHg lower DBP, and a 1.22 mmHg lower MAP.”

    Humansserumeach 10 ng/mL increasen = 923

    Association Between Serum 25-Hydroxyvitamin D and Blood Pressure in Young Adults

    Nutrients

  5. Calcitriol decreases blood pressure in mice (aged mice).

    “Calcitriol increased 24-hour urinary sodium excretion and reduced blood pressure in aged mice.”

    Animalsaged miceoral gavagekidney150 ng/kg per day8 weeksmales

    Calcitriol reverses age-related hypertension via downregulating renal AP1/AT₁R pathway through regulating mitochondrial function

    Clinical and experimental hypertension (New York, N.Y. : 1993)

All 306

What is vitamin D linked with?

133

Studies link vitamin D with 133 measures, among them mortality, type 2 diabetes and sarcopenia.

Mortality

downin humans8upin humans1RR 0.96

9 studies
  1. Vitamin D lowers the risk of mortality in humans (fixed-effect model) (RR = 0.96 (95% CI [0.92, 1.00], p = 0.04)).

    “Our meta‐analysis showed a statistically significant result regarding the benefit of vitamin D supplementation on all‐cause mortality with an RR = 0.96 (95% CI [0.92, 1.00], p = 0.04).”

    Human trialfixed-effect model2 and 6.1 yearsn = 30,320

    Vitamin D Supplementation and Mortality in the Elderly: A Review of a Meta-Analysis of Randomized Controlled Trials Using the REB Method

    Fundamental & clinical pharmacology

  2. Vitamin D lowers the risk of mortality in humans (RR 0.96, 95% CI [0.92, 1.00]).

    “RR = 0.96 (95% CI [0.92, 1.00]), p = 0.04.”

    Human trial

    Vitamin D Supplementation and Mortality in the Elderly: A Review of a Meta-Analysis of Randomized Controlled Trials Using the REB Method

    Fundamental & clinical pharmacology

  3. Vitamin D is associated with mortality in humans (HR 0.72, 95% CI 0.68–0.76).

    “for > 10 ng/mL-equivalent supplementation, mortality HR was 0.72 (0.68-0.76), while showing no corresponding association for skin malignancy.”

    HumansSupplementation modeled using pharmacy-dispensed purchases calibrated to predict serum 25(OH)D changes> 10 ng/mL-equivalent supplementation

    Severe vitamin D deficiency is linked to higher death rates

    Aging cell

  4. Vitamin D is linked with a lower risk of mortality in humans (stage 2 cardiovascular-kidney-metabolic syndrome, multimorbidity).

    “sufficient serum 25-hydroxyvitamin D [25(OH)D] levels demonstrated a potential antagonistic effect on multimorbidity-related mortality, particularly for CVD”

    Humansstage 2 cardiovascular-kidney-metabolic syndrome, multimorbidity

    Vitamin D deficiency, multimorbidity, and mortality in stage 2 cardiovascular-kidney-metabolic (CKM) Syndrome: evidence from the NHANES 2001-2018 cohort

    Renal failure

  5. Calcifediol is associated with mortality in humans (sarcopenia) (inflection point at 62.563 nmol/L).

    “Our results indicated a significant non-linear association between 25(OH)D concentration and both all-cause mortality and cardiovascular (CVD) mortality.”

    Humanssarcopenian = 1,666

    Association of 25-hydroxyvitamin D with all-cause and cardiovascular mortality among individuals with sarcopenia: evidence from the NHANES 2001-2006

    Frontiers in nutrition

  6. Calcifediol is linked with a lower risk of mortality in humans (compared with <30 nmol/L) (HR 0.69 (95% CI 0.57-0.84)).

    “higher vitamin D levels (30 to < 50, 50 to < 75, and ≥75 nmol/L) were associated with a lower risk of all-cause mortality: HR (95% CI) of 0.82 (0.69-0.98), 0.74 (0.62-0.88), and 0.69 (0.57-0.84), respectively.”

    Humanscompared with <30 nmol/Lserum≥75 nmol/L14.3 yearsn = 18,797

    Serum 25-hydroxyvitamin D levels and risk of all-cause and cause-specific mortality: A 14-year prospective cohort study

    Clinical nutrition (Edinburgh, Scotland)

  7. Calcifediol is linked with a lower risk of mortality in humans (serum 25(OH)D ≥75 nmol/L vs lowest group, fully adjusted model (Model 3)) (HR 0.48 (0.26, 0.87) vs lowest 25(OH)D group).

    “those with serum 25(OH)D concentrations ≥75 nmol/L had hazard ratios (HRs) and 95% confidence intervals (CIs) of 0.48 (0.26, 0.87) for all-cause mortality”

    Humansserum 25(OH)D ≥75 nmol/L vs lowest group, fully adjusted model (Model 3)≥75 nmol/Ln = 2,916

    Association of serum 25-hydroxyvitamin D concentrations with all-cause mortality among individuals with kidney stone disease: the NHANES database prospective cohort study

    Frontiers in endocrinology

  8. Calcifediol is linked with a lower risk of mortality in individuals with metabolic syndrome (HR 0.75 (0.64-0.89)).

    “An "L-shaped" nonlinear dose-response correlation was detected between 25(OH)D and cancer/all-cause mortality; the respective HRs (95% CI) were 0.75 (0.64-0.89)”

    Humansin individuals with metabolic syndrome

    Association of serum 25-hydroxyvitamin D with the incidence of 16 cancers, cancer mortality, and all-cause mortality among individuals with metabolic syndrome: a prospective cohort study

    European journal of nutrition

  9. Vitamin D is linked with a lower risk of mortality in humans.

    “A negative dose-response relationship was observed between 25(OH)D concentration and cognition impairment at baseline, as well as the odds of all-cause mortality during follow-up.”

    Humansmean (SD) follow-up of 3.8 (1.9) yearsn = 1,673

    Combined associations of vitamin D and cognitive function with all-cause mortality among older adults in Chinese longevity areas: A prospective cohort study

    Frontiers in public health

  10. Vitamin D raises the risk of mortality in patients already diagnosed.

    “other research suggests a potential worsening of brain pathology and an increase in mortality in patients already diagnosed.”

    Reviewin patients already diagnosed

    THE PARADOXICAL ROLE OF VITAMIN D IN ALZHEIMER'S DISEASE: A CRITICAL ANALYSIS OF THE SCIENTIFIC EVIDENCE

    Revista Ibero-Americana de Humanidades, Ciências e Educação

Type 2 diabetes

downin humans8no changein humans1HR 0.8–0.89

9 studies
  1. Vitamin D lowers the risk of type 2 diabetes in humans.

    “The EHDS was the top-ranked strategy in reducing FIN, HOMA-IR, HOMA of β-cell function, 2-h postload glucose, and new-onset T2D, and for improving normal glucose regulation.”

    Human trial

    Effects of Vitamin D Supplemental Dose in Adults with Prediabetes: A Systematic Review and Network Meta-Analysis

    Nutrition reviews

  2. Vitamin D lowers the risk of type 2 diabetes in humans (HR 0.89, 95% CI 0.80–0.99).

    “Meta-analysis of 4 trials (n = 5205; 936 T2D cases) obtained HR = 0.89 (CI = 0.80, 0.99).”

    Human trialn = 5,205

    Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial

    Nature communications

  3. Calcifediol is associated with type 2 diabetes in humans (overall) (HR 0.80 (0.62-1.04)).

    “the multivariable-adjusted hazard ratios (95% confidence intervals) for type 2 diabetes in those with vitamin D sufficiency were 0.80 (0.62-1.04) overall”

    Humansoverall14-year follow-upn = 3,604

    Serum 25-hydroxyvitamin D levels and risk of type 2 diabetes according to glycemic status: a prospective cohort study

    Nutrition & diabetes

  4. Vitamin D lowers the risk of type 2 diabetes in humans.

    “vitamin D supplementation at doses sufficient to achieve 25-hydroxyvitamin D levels ≥ 40 ng/ml appears to confer additional benefit in reducing diabetes risk”

    Reviewselected adults with prediabetes; supplementation sufficient to achieve 25-hydroxyvitamin D ≥40 ng/ml

    Serum 25(OH)D and diabetes risk in adults with prediabetes: evidence, potential mechanisms, and implications

    The Journal of clinical endocrinology and metabolism

  5. Vitamin D lowers the risk of type 2 diabetes in humans (Vitamin D-replete populations with prediabetes).

    “large trials show limited extra-skeletal benefits, apart from modest effects on cancer mortality and progression from prediabetes to Type 2 diabetes.”

    ReviewVitamin D-replete populations with prediabetes

    Vitamin D: Physiology, Pharmacology and Clinical Evidence for Supplementation-A Narrative Review

    Basic & clinical pharmacology & toxicology

  6. Vitamin D lowers the risk of type 2 diabetes in prediabetes with vitamin D deficiency or high metabolic risk.

    “vitamin D supplementation may reduce the risk of progression to T2DM”

    Reviewin prediabetes with vitamin D deficiency or high metabolic risk

    Prediabetes: diagnostic aspects, clinical features, and emerging therapeutic opportunities, with a focus on Vitamin D

    Journal of endocrinological investigation

  7. Vitamin D is associated with type 2 diabetes in humans.

    “vitamin D contributes significantly to maintaining the metabolic balance of calcium and phosphorus and supporting bone health while potentially affecting the development and incidence of diabetes”

    Review

    Beyond bones, vitamin D as a sunshine hormone in type 2 diabetes mellitus and its complications

    iScience

  8. Vitamin D lowers the risk of type 2 diabetes in humans (prediabetes).

    “In adults with prediabetes, moderate certainty of evidence suggested reduction in the rate of progression to diabetes.”

    Reviewprediabetes

    A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D

    The Journal of clinical endocrinology and metabolism

  9. Vitamin D lowers the risk of type 2 diabetes in humans (high-risk prediabetes).

    “for those with high-risk prediabetes because of its potential to reduce progression to diabetes”

    Reviewhigh-risk prediabetes

    Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline

    The Journal of clinical endocrinology and metabolism

More on Type 2 diabetes

Sarcopenia

downin humans8OR 0.47–0.92

8 studies
  1. Vitamin D is linked with a lower risk of sarcopenia in humans.

    “Higher vitamin D intake was associated with lower odds of sarcopenia”

    Humans

    Association Between Vitamin D Intake and Sarcopenia in Older Adults in South Korea: The Moderating Role of the Area Deprivation Index

    Asia-Pacific journal of public health

  2. Calcifediol is linked with a lower risk of sarcopenia in humans (OR 0.47, 95% CI 0.23-0.94).

    “Serum 25(OH)D concentrations were inversely associated with incident sarcopenia in men (odds ratio [OR] for the highest vs. lowest quartile, 0.47; 95% confidence interval [CI], 0.23-0.94; P for trend = 0.03)”

    Humans2-yearmales

    Sex-specific associations of serum 25-hydroxyvitamin D concentrations with incident sarcopenia in older adults: A 2-year follow-up study

    The journal of nutrition, health & aging

  3. Calcifediol is linked with a lower risk of sarcopenia in humans (compared to participants with 25(OH)D levels < 50 nmol/L) (OR 0.61, 95% CI 0.48-0.77).

    “0.61 (95% CI: 0.48, 0.77) for those with levels > 75 nmol/L”

    Humanscompared to participants with 25(OH)D levels < 50 nmol/L> 75 nmol/L

    Individual and joint association of serum 25-hydroxyvitamin D and folate levels with the risk of sarcopenia: a cross-sectional study from the NHANES 2011-2018

    Frontiers in nutrition

  4. Vitamin D is linked with a lower risk of sarcopenia in humans (patients with chronic liver disease) (OR 0.89, 95% CI 0.79-0.99).

    “each 10-nmol/L increase in 25(OH)D concentration was significantly associated with a decreased risk of sarcopenia (OR 0.89; 95%CI 0.79-0.99)”

    Humanspatients with chronic liver diseaseeach 10-nmol/L increasen = 1,402

    Associations of Serum Vitamin D with Sarcopenia in Patients with Chronic Liver Disease: A Population-Based Cross-Sectional Study

    Calcified tissue international

  5. Vitamin D is linked with a lower risk of sarcopenia in humans.

    “With increasing vitamin D, both the risk of sarcopenia and low muscle mass decreased significantly.”

    Humansn = 7,217

    Elucidating the Link Between Hypovitaminosis D and Sarcopenia: New Insights into Mechanisms and Threshold from the Evidence of NHANES 2011-2018

    Research SquarePreprint

  6. Vitamin D is associated with sarcopenia in humans (type 2 diabetes mellitus).

    “Age, lower BMI, reduced serum 25(OH)D, and reduced dietary protein and vitamin D intake were significantly associated with sarcopenia.”

    Humanstype 2 diabetes mellitusn = 110

    Association of Possible Sarcopenia or Sarcopenia with Body Composition, Nutritional Intakes, Serum Vitamin D Levels, and Physical Activity among Patients with Type 2 Diabetes Mellitus in Taiwan

    Nutrients

  7. Vitamin D is linked with a lower risk of sarcopenia in humans (non-obese probable sarcopenia) (OR 0.92 (95% CI 0.86, 0.98)).

    “but was seen in probable sarcopenia cases who were not obese (OR 0.92 (95% CI 0.86, 0.98))”

    Humansnon-obese probable sarcopenia

    Muscle Traits, Sarcopenia, and Sarcopenic Obesity: A Vitamin D Mendelian Randomization Study

    Nutrients

  8. Vitamin D lowers the risk of sarcopenia in humans.

    “while reducing the risk of falls, frailty, osteoporosis and sarcopenia.”

    Reviewfemales

    Vitamin D as a Modulator of Sarcopenia in Women: Interactions with Dietary Patterns and Physical Exercise

    Nutrients

More on Sarcopenia

Falls

upin humans3downin humans2RR 0.85

5 studies
  1. Cholecalciferol is associated with falls in nursing home residents (28.67% (p value 0.02)).

    “those residents taking cholecalciferol weekly where the ones with less falls (28.67%) (p value 0.02).”

    Humansin nursing home residents

    Vitamin D supplementation for fall prevention in nursing homes: Fall study in elderly people in Andalucía, Spain

    Revista espanola de geriatria y gerontologia

  2. Vitamin D raises the risk of falls in humans.

    “High intermittent doses may increase fall risk in some older adults.”

    Reviewhigh intermittent doses

    Vitamin D deficiency testing and supplementation in adult medical practice

    Annals of Innovation in Medicine

  3. Vitamin D is associated with falls in humans.

    “growing evidence suggesting an increased fall risk associated with highdose bolus administration”

    Reviewbolus administrationhigh dose

    Revisiting the Role of Vitamin D in Fracture Prevention in the Era of Mega-Trials

    Endocrinology and metabolism (Seoul, Korea)

  4. Vitamin D raises the risk of falls in humans.

    “Administration of high-dose intermittent vitamin D may increase falls, compared to lower-dose daily dosing.”

    Reviewhigh-dose intermittent

    A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D

    The Journal of clinical endocrinology and metabolism

  5. Vitamin D lowers the risk of falls in humans (RR 0.85, 95% CI 0.74-0.95).

    “Vitamin D supplementation at 800-1000 International Unit (IU)/d resulted in a lower risk of falls than placebo or no treatment (RR = 0.85, 95%CI: 0.74-0.95).”

    Review800-1000 IU/d

    Effect of vitamin D, calcium, or combined supplementation on fall prevention: a systematic review and updated network meta-analysis

    BMC geriatrics

Cognitive function

upin humans2mixedin humans1downin humans1

4 studies
  1. Vitamin D is associated with cognitive function in humans (sleep disturbance and mild cognitive impairment) (adjusted mean diff 3.78 (SE 1.77), p = 0.039).

    “Participants who took a daily dosage of 5000+ IU of vitamin D showed a marginally significant association with total MoCA score (adjusted mean (SE) = 3.78 (1.77); p = 0.039)”

    Humanssleep disturbance and mild cognitive impairment5000+ IU dailyn = 54

    Vitamin D supplement intake is associated with better cognition in persons with sleep disturbance and mild cognitive impairment

    Sleep medicine

  2. Vitamin D is associated with cognitive function in humans (moderate positive correlation).

    “Lower vitamin D levels were associated with reduced cognitive scores, weaker neuromuscular performance, altered calcium metabolism, and elevated inflammatory markers.”

    Humansn = 250

    The Impact of Vitamin D Deficiency on Cognitive and Neuromuscular Functions in Elderly Patients

    Neuro-Signals

  3. Vitamin D is associated with cognitive function in humans (geriatric memory patients).

    “Vitamin B6 and D deficiencies were associated with lower MMSE scores (p < 0.05).”

    Humansgeriatric memory patientsn = 167

    Vitamin B6 and vitamin D deficiency co-occurrence in geriatric memory patients

    Alzheimer's & dementia (Amsterdam, Netherlands)

  4. Vitamin D is associated with cognitive function in humans (meta-analyses).

    “Meta-analyses confirm mixed findings, typically indicating small or non-significant effects, with possible benefit restricted to vulnerable groups.”

    Reviewmeta-analyses

    Neurobiological mechanisms linking vitamin d signaling to cognitive decline and neurodegeneration: Untangling epidemiology, pathophysiology, and evidence

    World journal of experimental medicine

Osteoporosis

downin humans2upin humans1OR 0.948

3 studies
  1. Vitamin D is linked with a lower risk of osteoporosis in humans.

    “Vitamin D supplementation was associated with lower odds of both OA and OP.”

    Humans

    Prevalence and associated factors of osteoarthritis and osteoporosis among Chinese adults aged 60 years or older: a multicenter cross-sectional study

    Frontiers in public health

  2. Vitamin D is associated with osteoporosis in patients with sepsis.

    “Lower vitamin D levels after sepsis were also associated with a higher incidence of osteoporosis (P < 0.01).”

    Humansin patients with sepsis5 yearsn = 214

    Long-term bone metabolism outcomes in critically Ill patients with sepsis: a prospective series study

    BMC infectious diseases

  3. Cholecalciferol is linked with a lower risk of osteoporosis in humans (OR 0.948, 95% CI 0.901-0.998).

    “VD3 showed a modest protective association with OP (OR 0.948; 95% CI 0.901-0.998; p = 0.040)”

    Humansfemales

    Multinomial risk modeling of osteopenia and osteoporosis in Iraqi women: comparative contributions of osteoprotegerin and vitamin D3

    Journal, genetic engineering & biotechnology

More on Osteoporosis

Cognitive impairment

downin humans3−33% lower riskOR 0.695–0.92

3 studies
  1. Calcifediol is associated with cognitive impairment in humans (type 2 diabetes mellitus) (OR = 0.92, 95% CI: 0.88-0.97).

    “higher serum 25(OH)D3 levels were significantly associated with a lower prevalence of cognitive impairment”

    Humanstype 2 diabetes mellitusn = 221

    Serum 25(OH)D3 level is associated with cognitive impairment in middle-aged and elderly patients with type 2 diabetes mellitus

    Frontiers in endocrinology

  2. Vitamin D is linked with a lower risk of cognitive impairment in humans (adjusted for confounding factors; robust to vitamin supplements and comorbidities) (OR 0.695 (95% CI 0.534-0.905), p = 0.003).

    “serum Vitamin D (OR = 0.695, 95% CI: 0.534-0.905, p = 0.003) and FA (OR = 0.777, 95% CI: 0.604-0.999, p = 0.034) levels were inversely correlated with cognitive disorder risk”

    Humansadjusted for confounding factors; robust to vitamin supplements and comorbiditiesn = 2,582

    Relationship Between Serum Vitamins and Cognitive Impairment in the Elderly: A Study Based on the NHANES Database

    Brain and behavior

  3. Calcifediol is linked with a lower risk of cognitive impairment in humans (33% lower risk).

    “VD3 sufficiency was significantly associated with a 33% lower risk of cognitive impairment compared with VD3 deficiency”

    Humansn = 3,412

    Serum Vitamin D₃ Concentration, Sleep, and Cognitive Impairment among Older Adults in China

    Nutrients

More on Cognitive impairment

Bone fracture

downin humans3RR 0.74

3 studies
  1. Vitamin D lowers the risk of bone fracture in vitamin D-deficient and older populations.

    “Triangulated evidence provides strong and consistent support for a causal role of vitamin D in skeletal health, particularly in the prevention and treatment of rickets and osteomalacia, and in fracture risk reduction”

    Reviewin vitamin D-deficient and older populations

    Vitamin D and Health Outcomes: State-of-the-Art Review of Triangulated Evidence and Ongoing Controversies

    Current nutrition reports

  2. Vitamin D lowers the risk of bone fracture in humans.

    “Treatment of elderly people with vitamin D 800 IU daily will increase serum 25OHD levels to higher than 20 ng/mL and reduce fractures”

    Review800 IU daily

    Vitamin D and aging

    The Scientific Heritage

  3. Vitamin D lowers the risk of bone fracture in subgroup of RCTs with <1000 participants (RR 0.74, 95% CI 0.57-0.96).

    “intermittent or single high-dose vitamin D supplementation reduced the risk of fractures in the subgroup meta-analysis of RCTs that included fewer than 1000 participants (RR, 0.74 [95% CI 0.57-0.96]”

    Reviewin subgroup of RCTs with <1000 participantsintermittent or single high-dose

    Effects of intermittent or single high-dose vitamin D supplementation on risk of falls and fractures: a systematic review and meta-analysis

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

More on Bone fracture

Alzheimer's disease

downin humans2mixedin humans1OR 0.95

3 studies
  1. Cholecalciferol is linked with a lower risk of Alzheimer's disease in humans (adjusted OR 0.95, 95% CI 0.90-1.00).

    “Higher serum 25(OH)D levels were independently associated with lower odds of AD (adjusted OR per 1 ng/mL: 0.95; 95% CI: 0.90-1.00; p = 0.037).”

    Humansfemalesn = 514

    The relationship between vitamin D levels and Alzheimer's disease risk: insights from a centenarian study of Chinese women

    Frontiers in nutrition

  2. Vitamin D is linked with a lower risk of Alzheimer's disease in humans (β = -0.5725, 95% CI: -0.8349 to -0.3101, P = 0.0291).

    “IVW analysis indicated a significant inverse correlation between vitamin D levels and AD risk (β = -0.5725, 95% CI: -0.8349 to -0.3101, P = 0.0291)”

    Humans

    The Impact of Vitamin D on Alzheimer's Disease: A Mendelian Randomization Study

    Research SquarePreprint

  3. Vitamin D is associated with Alzheimer's disease in patients already diagnosed.

    “the nutrient has a controversial relationship with both reducing and exacerbating the worsening of Alzheimer's disease.”

    Reviewin patients already diagnosed

    THE PARADOXICAL ROLE OF VITAMIN D IN ALZHEIMER'S DISEASE: A CRITICAL ANALYSIS OF THE SCIENTIFIC EVIDENCE

    Revista Ibero-Americana de Humanidades, Ciências e Educação

More on Alzheimer's disease

Frailty

downin humans3−39% decreased oddsRR 0.71

3 studies
  1. Vitamin D is linked with a lower risk of frailty in humans (frailty phenotype) (OR 0.78, 95% CI 0.76–0.79, P < 0.001).

    “Baseline vitamin D levels were found to be significantly associated with frailty status (frailty phenotype: ORfrail 0.78, 95% CI [0.76, 0.79], P < 0.001”

    Humansfrailty phenotypen = 287,926

    The association between dynamic changes in vitamin D and frailty alterations: A prospective analysis of UK Biobank participants

    Journal of cachexia, sarcopenia and muscle

  2. Vitamin D lowers the risk of frailty in humans (highest vs. lowest level of vitamin D in prospective cohort studies) (RR 0.71, 95% CI 0.60–0.84).

    “Highest (vs. lowest) level of vitamin D in prospective cohort studies (with 14,153 participants and 2,137 cases with frailty) was significantly related to a 29% reduction in risk of frailty”

    Reviewhighest vs. lowest level of vitamin D in prospective cohort studiesn = 14,153

    Association between 25-hydroxy vitamin D levels and risk of frailty and pre-frailty in elderly adults: a systematic review and dose-response meta-analysis of epidemiologic studies with GRADE assessment

    Journal of translational medicine

  3. Vitamin D lowers the risk of frailty in combination with omega-3 and a simple home exercise program (39% decreased odds).

    “the 3 treatments combined showed a significant 39% decreased odds of becoming prefrail compared to the control.”

    Reviewin combination with omega-3 and a simple home exercise program3 yearsn = 2,157

    The Effects of Vitamin D Supplementation on Musculoskeletal Health: The VITAL and DO-Health Trials

    The journals of gerontology. Series A, Biological sciences and medical sciences

Benign paroxysmal positional vertigo

downin humans1

1 study
  1. Vitamin D lowers the risk of benign paroxysmal positional vertigo in humans (idiopathic BPPV) (0.75 fewer clinical BPPV recurrences per one person year).

    “Participants were analysed based on original group assignment with intention to treat protocol and vitamin D replacement in Group A was associated with 0.75 fewer clinical BPPV recurrences per one person year.”

    Human trialidiopathic BPPV12 monthsn = 39

    Falls and physical function in older patients with Benign Paroxysmal Positional Vertigo (BPPV): findings from a placebo controlled, double blinded randomized control trial (RCT) investigating efficacy of vitamin D treatment in lowering the recurrence rate of BPPV

    Aging clinical and experimental research

  2. Vitamin D lowers the risk of benign paroxysmal positional vertigo in humans with diet and Canalith Repositioning Procedure versus diet alone with CRP (-0.75 per person-year, P = 0.035).

    “0.75 fewer clinical BPPV recurrences per one person year (P = 0.035) compared to Group B.”

    Human trialwith diet and Canalith Repositioning Procedure versus diet alone with CRP12 month

    Falls and physical function in older patients with Benign Paroxysmal Positional Vertigo (BPPV): findings from a placebo controlled, double blinded randomized control trial (RCT) investigating efficacy of vitamin D treatment in lowering the recurrence rate of BPPV

    Aging clinical and experimental research

More on Benign paroxysmal positional vertigo

Fracture risk

upin humans1HR 1.52

1 study
  1. Cholecalciferol raises the risk of fracture risk in humans (compared to placebo) (HR 1.52, 95% CI 1.06-2.18).

    “1600 IU/day (compared to placebo: HR = 1.52, 95% CI = 1.06-2.18)”

    Human trialcompared to placebo1600 IU/daymean 4.1-year

    The effect of vitamin D₃ supplementation on fracture incidence in an aging population - The Finnish vitamin D trial

    Bone

Fragility fracture

downin humans1

1 study
  1. Cholecalciferol lowers the risk of fragility fracture in humans (T-scores -1.5 to -2.5) (0.7%-2.0% vs 5.2%).

    “Eight patients (5.2%) in the placebo group had fresh fragility fractures; two (1.3%), three (2.0%), and one (0.7%) in the conventional, micronized, and liposomal groups, respectively; χ2 = 7.42; p = 0.059.”

    Human trialT-scores -1.5 to -2.524 monthsfemales

    Vitamin D supplementation and bone health in post-menopausal women: a 24-month randomized controlled intervention with enhanced bioavailability formulations

    European journal of clinical nutrition

More on Fragility fracture

Five-times sit-to-stand test

downin humans1

1 study
  1. Vitamin D is associated with five-times sit-to-stand test in humans (at risk of sarcopenia, H-RT group) (rp = -0.55).

    “In both groups, lower levels of vitamin B12 (H-RT: rp = -0.52; MT: rp = -0.50) and vitamin D (H-RT: rp = -0.55; MT: rp = -0.69) were associated with worse 5STS performance.”

    Human trialat risk of sarcopenia, H-RT group32 weeksfemales

    Nutritional intake as a determinant of high-speed resistance and multicomponent training efficacy on strength in older women at risk of sarcopenia. A randomized clinical trial

    Clinical nutrition (Edinburgh, Scotland)

Coronary revascularization

downin humans1

1 study
  1. Cholecalciferol lowers the risk of coronary revascularization in humans.

    “The same was true of coronary revascularisation, although the confidence interval for the hazard ratio included the null (0.89, 0.78 to 1.01;, supplementary figs 16 and 17).”

    Human trialfive yearsn = 21,302

    Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial

    BMJ (Clinical research ed.)

All 133

What acts on vitamin D?

1

Studies name diet as acting on vitamin D.

Diet

downin humans1

1 study
  1. Diet decreases vitamin D in the UK.

    “National Diet and Nutrition Survey data show significant declines in vitamin D intake - especially among lower intake percentiles”

    Reviewin the UK

    Vitamin D in the UK: an urgent call to redefine the threshold for deficiency

    Frontiers in endocrinology

More on Diet

Trials

43 of 307 about aging

Who is developing vitamin D?

2 companies: OPKO Health and BPGbio.

Trials
Companies
  • OPKO HealthcalcifediolPhase 2COVID-19, coronavirus
  • BPGbiocalcitriolPhase 1chemotherapy induced alopecia

Trial sponsors

Funding

70 grants since 2016

Japan Society for the Promotion of Science¥135MNational Institute of Diabetes and Digestive and Kidney Diseases$8.5MNational Institute on Aging$12.2M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Independent labs report longer mouse lifespan and less senescence in human cells with vitamin D forms. Human trials report mixed telomere and mortality results and no clear effects on dementia or sarcopenia. Aging-related trials are registered; some trials across uses ended over a year ago without posted results, and some papers declare company ties.

  2. Summary rewritten as its findings changed.

    As it read before

    Cholecalciferol extends worm lifespan and calcitriol reduces senescence in human cells in independently replicated studies; human trials disagree on telomere and frailty outcomes and show no clear effect on fractures. There are 39 aging-related registrations; across uses, 130 trials ended over a year ago without posted results. Human papers declare company ties, and Organon sponsors trials.

  3. Summary rewritten as its findings changed.

    As it read before

    Independent labs report longer mouse lifespan with cholecalciferol and reduced human-cell senescence with calcitriol; human trials report unchanged or increased fractures and mixed frailty outcomes. Twenty registered trials concern aging; 131 trials across all uses ended over a year ago without posted results or citing papers. Some papers declare company ties, and Organon sponsors two trials.

  4. Summary rewritten as its findings changed.

    As it read before

    Independent labs report lower human mortality and longer mouse lifespan with cholecalciferol; calcifediol associates with higher human mortality, and human trials report no reduction in nonvertebral fractures or improvement in physical function. Nine registered trials concern aging; 140 trials across uses ended over a year ago without posted results or citing papers. Some papers declare company ties, and Organon sponsors two trials.

  5. Summary rewritten as its findings changed.

    As it read before

    Human studies associate vitamin D with lower mortality, independently replicated, but others report higher mortality; a trial reports slower leukocyte telomere attrition, while others report no fracture or physical-function benefit. Nine registered trials concern aging; across all uses, 140 ended over a year ago without posted results or citing papers. Authors include company employees, and papers declare developer and other company ties.

Latest

The Journal of Nutrition

Omega-3s did not significantly cut major cardiovascular events

Major cardiovascular events had a hazard ratio of 0.92 versus placebo, with 1 meaning no difference; heart attacks were less frequent.Major cardiovascular events had a hazard ratio of 0.92 versus placebo, with 1 meaning no difference; heart attacks were less frequent.

Randomized trial · 25,871 peopleCardiovascular disease
Food Science & Nutrition

Low vitamin D linked to greater frailty in adults

Low versus normal vitamin D was linked to a 76% higher relative risk of developing frailty in China and 27% in England.Low versus normal vitamin D was linked to a 76% higher relative risk of developing frailty in China and 27% in England.

Cohort studyPopulations

See all 4,014 papers on vitamin D